在伊朗的急性冠状动脉综合征中,提卡格勒和克洛皮多格勒之间的成本效益比较
Amir Hashemi-Meshkini1, Amirmohammad Tajik2, Nayyereh Ayati1
1Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
The journal of Tehran Heart Center
|August 28, 2023
概括
与克洛皮多格雷尔相比,蒂卡格雷勒是伊朗急性冠状动脉综合征 (ACS) 患者的成本有效的抗血小板药物. 这一发现支持对伊朗ACS治疗的有效资源配置.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 心脏病学 心脏病学
背景情况:
- 急性冠状动脉综合征 (ACS) 对健康构成重大负担.
- 评估抗血小板疗法,如蒂卡格洛尔和克洛皮多格雷尔,对于患者的治疗结果和医疗保健成本至关重要.
研究的目的:
- 确定蒂卡格雷勒与克洛皮多格雷尔在伊朗ACS患者的成本效益.
- 为伊朗的ACS管理提供医疗保健政策和资源分配的信息.
主要方法:
- 一年决策树模型与20年马尔科夫模型相结合,模拟了长期成本和效率.
- 临床疗效数据来源于PLATO试验和其他研究.
- 成本数据基于伊朗公共部门的价格;敏感性分析确保了稳定性.
主要成果:
- 与克洛皮多格雷尔相比,蒂卡格雷勒在20年内每1000名患者增加2.39美元的额外成本.
- 提卡格勒尔每1000名患者获得了7.2个质量调整寿命年 (QALY).
- 增量成本效益比 (ICER) 为每个获得的QALY为332.03美元.
结论:
- 与克洛皮多格雷尔相比,蒂卡格雷勒是伊朗ACS患者的成本有效的抗血小板治疗方法.
- 研究结果表明,蒂卡格勒可以帮助伊朗的政策制定者有效地分配ACS护理的资源.
相关概念视频
Acute Coronary Syndrome III: Diagnostic Studies
10
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
560
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
560
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Acute Coronary Syndrome I: Introduction
30
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
30
Acute Coronary Syndrome IV: Interprofessional Care
12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12


